PCSK9 inhibitors in the management of atherosclerotic cardiovascular disease: Current clinical trials and future directions

被引：0
|
作者：
Nie, Wenyi [1 ]
Yue, Yingbin [2 ,3 ]
Hu, Jingqing [1 ]
机构：
[1] Changchun Univ Chinese Med, Changchun 130117, Peoples R China
[2] Xinjiang Med Univ, Affiliated Hosp 1, Urumqi 830054, Peoples R China
[3] Xinjiang Med Univ, State Key Lab Pathogenesis, Prevent & Treatment High Incidence Dis Cent Asia, Urumqi 830054, Peoples R China
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
基金：
国家重点研发计划;
关键词：
PCSK9; inhibitors; Clinical trial; Existing evidence; Future perspectives;
D O I：
10.1016/j.atherosclerosis.2024.119043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease
    Bittner, Vera A.
    Giugliano, Robert P.
    Brinton, Eliot A.
    Guyton, John R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 835 - 843
  • [2] Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
    Wojcik, Cezary
    POSTGRADUATE MEDICINE, 2017, 129 (08) : 801 - 810
  • [3] PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
    Delialis, Dimitrios
    Dimopoulou, Maria-Angeliki
    Papaioannou, Maria
    Kotsira, Georgia
    Maneta, Eleni
    Mavraganis, Georgios
    Loutos, Christos
    Georgiopoulos, Georgios
    Stamatelopoulos, Kimon
    CURRENT PHARMACEUTICAL DESIGN, 2023, 29 (23) : 1802 - 1824
  • [4] PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease
    Landmesser, Ulf
    CARDIOVASCULAR RESEARCH, 2017, 113 (08) : E24 - E25
  • [5] Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
    Dave L. Dixon
    Lauren G. Pamulapati
    John D. Bucheit
    Evan M. Sisson
    Shawn R. Smith
    Caroline J. Kim
    George F. Wohlford
    Jonah Pozen
    Current Atherosclerosis Reports, 2019, 21
  • [6] Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
    Dixon, Dave L.
    Pamulapati, Lauren G.
    Bucheit, John D.
    Sisson, Evan M.
    Smith, Shawn R.
    Kim, Caroline J.
    Wohlford, George F.
    Pozen, Jonah
    CURRENT ATHEROSCLEROSIS REPORTS, 2019, 21 (05)
  • [7] PCSK9 INHIBITORS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE
    Knijnik, Leonardo M.
    Rivera, Manuel
    Cardoso, Rhanderson
    Fernandes, Gilson
    Fernandes, Amanda
    Orringer, Carl
    Cohen, Mauricio
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 41 - 41
  • [8] PCSK9 inhibitors in the prevention of cardiovascular disease
    James Latimer
    Jonathan A. Batty
    R. Dermot G. Neely
    Vijay Kunadian
    Journal of Thrombosis and Thrombolysis, 2016, 42 : 405 - 419
  • [9] PCSK9 Inhibitors Current clinical Relevance
    Vogt, A.
    INTERNIST, 2017, 58 (02): : 196 - 201
  • [10] PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
    Nicholls, Stephen J.
    KARDIOLOGIA POLSKA, 2023, 81 (02) : 115 - 122
12345